Protocols
65 protocol(s) meet the specified criteria
Disease Site: Breast - Female
Protocol No.TitleStatus
11-1474Accountability for Cancer Care through Undoing Racism and Equity (ACCURE)Open
13-0736 Improving endocrine therapy utilization in racially diverse populationsOpen
15-102-14A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and CapecitabineOpen
15-2304Implementing Breast Cancer Care Efficiency in Zambia through Specialized Health Provider Training and mhealth Evaluation of Patient OutcomesOpen
16-1634Comparative Effectiveness of Breast Cancer Screening, Diagnosis, and Management in Community PracticeOpen
16-1775Developing a Medication Assistance Program for Uninsured and Under-insured Patients with Metastatic Breast Cancer: Key Informant Conference Participant Data Open
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
201209135A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast CancerOpen
3000-PN162-01-001Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian CancerOpen
A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Open
A011502-CIRBA Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial Open
A211201CHANGE IN MAMMOGRAPHIC DENSITY WITH METFORMIN USE: A COMPANION STUDY TO NCIC STUDY MA.32Open (affiliates only)
A221405A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)Open
AFT-25Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: a Phase III Prospective Randomized TrialOpen
ALTERNATE/A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III StudyOpen
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid TumorsOpen
B2151009Phase 1B Study to Assess the Safety, Tolerbaility, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)Open
D6410C00001A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid TumorsOpen
E1Z11A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Open (affiliates only)
E2112-CIRBA Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast CancerOpen
GO29322A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients with Locally Advanced or Metastatic Solid TumorsOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
I3Y-MC-JPBOA Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or MelanomaOpen
INO-VT-464-CL-006A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast CancerOpen
LCCC1405Comparison of the specificity of acoustic angiography (Micro-tumor detection by quantifying tumor-induced vascular abnormalities) to the specificity of conventional ultrasoundOpen
LCCC1410Impact of physical activity on biomarkers of aging and body composition among breast cancer survivors age 65 and older Open
LCCC1414Evaluation of stationary digital breast tomosynthesis in a screening call back population and in patients with calcifications Open
LCCC1419Establishment of Breast Cancer Brain Metastases (BCBM) Registry to Support Research of Molecular Drivers of BCBMOpen
LCCC1501The Impact of Real Time, Three-Dimensional Photographic Simulation on Satisfaction with Decisions about Breast Reconstruction Open
LCCC1512Evaluation of the accuracy of new-generation pedometers in older adult patients with advanced cancers Open
LCCC1525Phase II Study Of Pembrolizumab Therapy Following a Single Priming Dose of Cyclophosphamide in Patients With Metastatic Triple Negative Breast Cancer (TNBC)Open
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1540Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation.Open
LCCC1545Computerized Cognitive Behavioral Therapy in Recently Treated Breast Cancer PatientsOpen
LCCC1609Improving endocrine therapy utilization in racially diverse populationsOpen
LCCC1611Establishment of a novel breast cancer cohort in MalawiOpen
LCCC1616Developing a medication assistance program for uninsured and underinsured patients with metastatic breast cancer Open
LCCC1618Validation of Activity Tracker Data as a Measure of Fatigue, Symptom Burden, Physical Function and Quality of Life in Adults Receiving Taxane Therapy for Treatment of Stage II/III Breast CancerOpen
LCCC1622A Single Arm Evaluation of False Negative Rate of Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1630Get Real and HEEL Research ProgramOpen
LCCC1631A Qualitative Study of Patients who chose Contralateral Prophylactic Mastectomy (CPM) Open
LCCC1642Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast CancerOpen
LCCC1719A Psychosocial Intervention to Improve Outcomes for Parents with Advanced CancerOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
MK-3475-355A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355)Open (affiliates only)
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NRG-BR002-CIRBA Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Open
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
NSABP-B-43A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by LumpectomyOpen (affiliates only)
NSABP-B-46-IA Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerOpen (affiliates only)
NSABP-B-47-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerOpen (affiliates only)
NSABP-B-54-IPhase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapyOpen (affiliates only)
ONT-380-206Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)Open
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RU011301IAdjuvant Ado-Trastuzumab Emtansine (TDM-1) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerOpen
S1207-CIRBPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
S1416-CIRBPhase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerOpen
S1418-CIRBPhase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant ChemotherapyOpen
TBCRC-030A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) BiomarkerOpen
TBCRC-034The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle BiopsyOpen
TBCRC-040Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast CancerOpen
TRT-001A Multi-center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA Followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard TherapyOpen
Z31602Z 31602 - Breast and Cervical Cancer Survivorship Among HIV-Positive Women in ZambiaOpen